Addressing Racial Disparities in Health Care

Latest News

Doctors Treating Minority Ovarian Cancer Patients May Not Be Aware of Their Own Implicit Biases

Evidence strongly suggests a higher mortality rate and lack of high-quality treatment among Black ovarian cancer patients than white patients. Although the exact reason for this disparity isn’t clear, factors ranging from socioeconomic inequality to access to health care may play roles.

Learn More

How Would You Treat a 60-Year-Old Woman with Relapsed Refractory Myeloma?

A 60-year-old woman was previously treated with a standard VRD combination followed by a stem cell transplant on lenalidomide maintenance therapy, which was stopped due to diarrhea. Three years later she had an increase in her "M protein" and her myeloma has returned. How would you approach her treatment?

Learn More

Weighing the Risks of Multiple Myeloma Therapy in the Time of COVID-19

As the COVID-19 pandemic spread across the country, cancer specialists had to weigh the risks of treating multiple myeloma to prevent morbidity and mortality, with the dangers of virus exposure in their patients. SurvivorNet's experts say treatment decisions often hinge on geographic location.

Learn More

How Top Institutions Are Working to Reduce Racial Disparities

Black Americans have a two- to three-fold incidence of multiple myeloma compared to whites, yet they are significantly underrepresented in clinical trials. Issues with access, eligibility, and a lack of information from providers prevent many Black patients from participating.

Learn More

What We’re Learning About Isatuximab and How It’s Being Used to Treat Multiple Myeloma Patients

The recent FDA approval of isatuximab in combination with pomalidomide and dexamethasone has opened up another avenue of treatment for multiple myeloma patients who have already undergone two prior lines of therapy.

Learn More

Belamaf is ‘First-In-Class’ New Therapy for Relapsed/Refractory Myeloma, But What’s Its Role in the Toolkit?

In August, the FDA granted belantamab mafodotin (Belamaf) accelerated approval for patients with relapsed or refractory multiple myeloma who've received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Learn More

Next Level HRD Testing and How to Make Better Decisions

Dr. Thomas Herzog notes the importance of an HRD test, “Getting an HRD for me would be important. I think the next gen sequencing doesn’t lead to new treatments all that often. My counter-argument to that is that we’re learning more and more. We really want to move the field forward and we need to get that information."

Learn More

Has COVID-19 Changed Treatment?

Many oncologists are wondering: How has COVID-19 changed treatment? Dr. Elizabeth Jewell of Memorial Sloan Kettering says, “You can safely get COVID-positive patients and cancer patients through treatment and through surgery.” Many are following ACS guidelines around how to stratify cases.

Learn More